XOMA (NASDAQ:XOMA) Stock Price Crosses Above 200 Day Moving Average of $19.93

XOMA Co. (NASDAQ:XOMA) shares passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $19.93 and traded as high as $24.62. XOMA shares last traded at $24.38, with a volume of 7,113 shares.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $74.00 price target on shares of XOMA in a report on Friday, February 16th.

XOMA Price Performance

The stock’s 50-day moving average is $24.36 and its two-hundred day moving average is $19.99. The company has a market capitalization of $286.10 million, a PE ratio of -6.09 and a beta of 0.58. The company has a current ratio of 8.68, a quick ratio of 8.68 and a debt-to-equity ratio of 1.34.

XOMA (NASDAQ:XOMA) last announced its quarterly earnings data on Friday, March 8th. The biotechnology company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.13). The company had revenue of $1.83 million for the quarter, compared to the consensus estimate of $1.01 million. XOMA had a negative net margin of 886.91% and a negative return on equity of 25.17%. On average, equities analysts predict that XOMA Co. will post -1.73 EPS for the current year.

Institutional Investors Weigh In On XOMA

Several institutional investors have recently bought and sold shares of XOMA. Citigroup Inc. grew its position in XOMA by 100.5% during the 1st quarter. Citigroup Inc. now owns 3,063 shares of the biotechnology company’s stock worth $86,000 after purchasing an additional 1,535 shares during the period. Dimensional Fund Advisors LP acquired a new stake in XOMA during the first quarter worth about $217,000. UBS Group AG raised its position in XOMA by 23.5% during the first quarter. UBS Group AG now owns 3,632 shares of the biotechnology company’s stock valued at $101,000 after acquiring an additional 691 shares in the last quarter. State Street Corp boosted its position in XOMA by 1.1% in the 1st quarter. State Street Corp now owns 131,340 shares of the biotechnology company’s stock worth $3,675,000 after purchasing an additional 1,464 shares in the last quarter. Finally, First Manhattan Co. grew its stake in shares of XOMA by 33.3% during the 1st quarter. First Manhattan Co. now owns 10,000 shares of the biotechnology company’s stock worth $279,000 after purchasing an additional 2,500 shares during the period. 95.92% of the stock is currently owned by institutional investors and hedge funds.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.